The CHMP recommended for approval nivolumab/ipilimumab for patients with MSI-H and dMMR unresectable or metastatic colorectal cancer.

Experts in multiple myeloma discussed real-world efficacy and safety data associated with the use of GPRC5D-targeting bispecific agents to treat patients with R/R multiple myeloma.

A leader from the adolescent and young adult lymphoma space discusses how collaboration between adult and pediatric oncologists has transformed the field.

“When thinking about treatment options for refractory DLBCL you consider: Is it safe to give an older patient CAR T-[cell therapy]?,” said Jennifer Amengual, MD.

Clinicians focused on CLL, follicular lymphoma, and MCL gathered during a Frontline Forum to discuss the use of BTKi in each respective disease state.

Patients with any type of cancer showed better QOL after undergoing the radical remission multimodal intervention method.

David M. Swoboda, MD, and Andrew Kuykendall, MD, spoke about the current treatment strategies and potential advancements that may improve outcomes such as spleen volume reduction in the myelofibrosis field.

The FDA has approved revumenib (Revuforj) for the treatment of patients with relapsed/refractory acute leukemia with a KMT2A translocation in adult and pediatric patients 1 year and older.

Barriers and gaps in treatment and care for patients diagnosed with gynecologic cancers were reported in a recent survey.

Developers are expected to file a supplemental NDA for revumenib in NPM1-mutated AML in the first half of 2025.

Data from the phase 2/3 KEYNOTE-483 trial support the CHMP’s recommendation for approving pembrolizumab/chemotherapy in the European Union.

HER-directed treatment approaches in the tumor-agnostic field were the highlight of the discussion for a panel of experts who convened at WCLC 2024.

Patients with Philadelphia chromosome–positive CML in chronic phase will no longer be required to fast before taking nilotinib tablets.

Data from the phase 2b ReNeu trial may support mirdametinib as a valuable new treatment option for adults and children with NF1-PN.

Survival data from the interim analysis of the phase 3 DREAMM-7 trial will be presented at the 2024 ASH Annual Meeting.

Nicole Lamanna, MD, discusses addressing a clinically unmet need among patients with CLL who have relapsed on multiple prior lines of therapy.

Denileukin diftitox plus pembrolizumab yields objective responses and clinical benefit in patients with recurrent solid tumors.

Three patients treated at the first dose level of BAFF CAR-T cells experienced minimal adverse effects in a phase 1 study.

Treatment with pimicotinib also yields meaningful improvements in stiffness and pain symptoms among patients with TGCT in the phase 3 MANEUVER study.

Personalized therapy for non–small cell lung cancer has evolved significantly with the advent of comprehensive molecular testing.

Stereotactic body radiotherapy showed noninferior biochemical or clinical failure compared with standard radiotherapy in select patients with prostate cancer.

Data from TROPION-Lung05, TROPION-Lung01, and TROPION-PanTumor01 support the new BLA for dato-DXd in advanced or metastatic EGFR-mutated NSCLC.

Given that well-differentiated grade 3 NETs are relatively new, standard-of-care treatment options are undefined.

Camizestrant showed better progression-free survival than fulvestrant across various subgroups of patients with advanced breast cancer.

Treatment with THIO/cemiplimab was generally well-tolerated among patients with advanced NSCLC in the phase 2 THIO-101 study.